FUNDACION PARA LA INVESTIGACION MEDICA APLICADA - Spain 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:700-800
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:600-700
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2013
Criterium:Position:
Overall Score:600-700
Total Project Funding per Partner:300-400
Total Number of Projects:66
Total Project Funding:400-500
Partner Constancy:58
Project Leadership Index:69
Diversity Index:61
2012
Criterium:Position:
Overall Score:700-800
Total Project Funding per Partner:500-600
Total Number of Projects:68
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:46
Project Leadership Index:75
Diversity Index:41
2011
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:400-500
Total Number of Projects:500-600
Total Project Funding:500-600
Networking Rank (Reputation):800-900
Partner Constancy:> 1000
Project Leadership Index:100-200
Diversity Index:> 1000
2010
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2009
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2008
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:700-800
Total Number of Projects:900-1000
Total Project Funding:600-700
Networking Rank (Reputation):900-1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:500-600
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:900-1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2022-12-31 ):

Total Project Funding:

Funding per Partner:

Projects:

Leadership:

Total number of projects: 32
As coordinator: 2
As participant: 18
Sole participant: 12
Coordinator / Participant Ratio: 0.11*

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2021 0 3.381.889 509.184 1
2020 333.865 14.056.649 1.034.395 2 3
2018 2.158.122 1.279.782 2.405.995 2 1
2017 0 2.512.169 247.873 1
2015 5.920.122 0 1.360.122 2
2014 223.002 2.415.767 643.502 1 1
2013 849.197 27.470.147 2.596.453 4 4
2012 0 3.197.783 1.733.149 3
2011 3.575.220 20.928.350 2.472.606 3 3
2010 0 2.999.500 172.500 1

Networking:

Partners:

Institution:Projects [No]:
UNIVERSIDAD DE NAVARRA5
UNIVERSITEIT MAASTRICHT5
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE4
MEDIZINISCHE HOCHSCHULE HANNOVER4
INSERM TRANSFERT3
KATHOLIEKE UNIVERSITEIT LEUVEN3
KLINIKUM DER UNIVERSITAET ZU KOELN3
MOSAIQUES DIAGNOSTICS3
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN3
ACS BIOMARKER BV2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
CHARITE UNIVERSITAETSMEDIZIN BERLIN2
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS2
DEUTSCHES KREBSFORSCHUNGSZENTRUM2
DIGNA BIOTECH SL2
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM2
FIRALIS SAS2
FONDATION TRANSPLANTATION2
HOSPICES CANTONAUX CHUV2
MEDIZINISCHE UNIVERSITAET WIEN2
RANDOX CLINICS LIMITED2
RHEINISCHE FRIEDRICH WILHELMS UNIVERSITAET BONN2
UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA2
UNIVERSITAETSKLINIKUM HEIDELBERG2
UNIVERSITY COLLEGE LONDON2
UNIVERSITY OF GLASGOW2
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM1
ACADEMISCH ZIEKENHUIS LEIDEN1
ACADEMISCH ZIEKENHUIS MAASTRICHT1
ADURO BIOTECH EUROPE BV1
ALBERT LUDWIGS UNIVERSITAET FREIBURG1
AMSTERDAM MOLECULAR THERAPEUTICS BV1
ARTTIC1
ASSOCIAZIONE HAND IN HAND1
AZIENDA OSPEDALIEROUNIVERSITARIA DI PARMA1
BIOINVENT INTERNATIONAL AB1
BIONEER1
BRAINS UNLIMITED BV / TRADE NAME SCANNEXUS1
CARDIOMYOPATHY UK1
CELLULAR THERAPEUTICS LIMITED1
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS1
CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III1
CLINICA MEDITERRANEA1
CONSIGLIO NAZIONALE DELLE RICERCHE1
CROWDHELIX LIMITED1
CROWDHELIX LIMITED1
EINDHOVEN UNIVERSITY OF TECHNOLOGY1
EMERGENTEC BIODEVELOPMENT1
EMORY UNIVERSITY NON PROFIT CORP1
EXPLORA1
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMOURI1
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA1
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE1
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS1
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA FUNDACION INCLIVA1
FUNDACION PUBLICA MIGUEL SERVET1
FUTURESYNTHESIS SP ZOO1
FYZIOLOGICKY USTAV AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE1
GENIBET BIOPHARMACEUTICALS1
GLYCOCHECK BV1
GLYCOTOPE1
GOETEBORGS UNIVERSITET1
GREENPHARMA S A1
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE1
INLECOM INNOVATION ASTIKI MI KERDOSKOPIKI ETAIREIA1
INNOVATIVE TECHNOLOGIES IN BIOLOGICAL SYSTEMS1
INSTITUT GUSTAVE ROUSSY1
INSTITUT PASTEUR DU MAROC1
INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA1
INTANA BIOSCIENCE1
ISTITUTO AUXOLOGICO ITALIANO1
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI1
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI1
JENACELL1
KAROLINSKA INSTITUTE1
KING'S COLLEGE LONDON1
KITE INNOVATION LIMITED1
KLINIKUM DER UNIVERSITAET REGENSBURG1
KLINIKUM DER UNIVERSITAT MUNCHEN1
KRZYSZTOF KUCHARCZYK TECHNIKI ELEKTROFORETYCZNE SPZOO1
LEADARTIS SL1
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE1
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN1
LUNDS UNIVERSITET1
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN1
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV1
MEDIZINISCHE UNIVERSITAET GRAZ1
MEDIZINISCHE UNIVERSITAT GRAZ1
MENOUFIYA UNIVERSITY1
MILTENYI BIOTEC1
MODUS RESEARCH AND INNOVATION LIMITED1
MOTAC FRANCE1
MRC HOLLAND BV1
NATIONAL RESEARCH CENTER1
OSPEDALE SAN RAFFAELE1
OXI GEN LAB1
PERCUROS BV1
PLURISTEM1
PROGREDUM1
RIBOLOGICAL1

Constancy:

Total number of partners: 193
Partner loyalty:
Frequent Partner: (> 2 projects): 33
Rare Partner: 160
Frequent / Rare Partner Ratio: 0.21

Project overview:

Start dateProjectacronymrolefundingpartners
2021-04-01AI-enabled RNA nanotechnology DElivery SysTem for INformATION transfer into cells. DESTINATIONparticipant3.381.8897
2020-07-01Synapses between Leukaemia and its Neighbouring Cells SyLeNCecoordinator160.9321
2020-05-01DevelOpmeNt of Cancer RNA TherapEutics cONCReTEparticipant2.060.80017
2020-03-01Elucidating transcriptional rewiring on hematological malignancies via computational methods LINKERcoordinator172.9321
2020-01-01COMORBIDITY MECHANISMS OF ANXIETY AND PARKINSON’S DISEASE AND-PDparticipant5.995.84912
2020-01-01MiCrovasculaR rarefaction in vascUlar Cognitive Impairement and heArt faiLure CRUCIALparticipant6.000.00014
2018-06-01Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours Tumor-Treg-Targetingparticipant1.279.7824
2018-04-01Investigating the role of the long noncoding transcriptome in chromatin replication NonChroRepcoordinator2.000.0001
2018-02-15Advancing cancer immunotherapy using natural killer cells for hematological and metastatic cancers CINKcoordinator158.1221
2017-01-01European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry EN_ACTI2NGparticipant2.512.16913
2015-12-01Characterization of Key Epigenetic Targets in Hepatic Fibrosis and Hepatocellular Carcinoma Development. Generation of New Antifibrotic and Antitumoral Drugs. TARGEPILIVERcoordinator170.1221
2015-09-01Professional cross-priming for ovary and prostate cancer PROCROPcoordinator5.750.0007
2014-06-01New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming REPROPARKparticipant2.415.7672
2014-04-01Interspecies endotheliarization for organ xenotransplantation INTEREXTcoordinator223.0021
2013-11-01Immunostimulatory Agonist antibodies for Cancer Therapy IACTparticipant5.995.74710
2013-11-01ROLE OF THE TRANSCRIPTION FACTOR FOXP1 IN B CELL FUNCTION AND LYMPHOMAGENESIS LYMFOXP1coordinator230.0371
2013-10-01The European non-coding RNA network RNATRAINparticipant3.474.40011
2013-10-01The role of miRNAs in KRAS-driven Non-Small Cell Lung Cancer KRASMIRcoordinator100.0001
2013-09-01Targeting cardiac fibrosis for heart failure treatment FIBRO-TARGETSparticipant6.000.00011
2013-09-01Role of DNA methylation in the regulation of lincRNAs in Hematological Malignancies LINCMHEMcoordinator352.8241
2013-03-01The roles of juvenil NMDA receptors in synapse maturation and elimination and their association with cognition NMDAR-SYNPRUNcoordinator166.3361
2013-02-01Heart OMics in AGEing HOMAGEparticipant12.000.00018
2012-11-01"From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" BRAINVECTORSparticipant1.597.78312
2012-09-01Supply-rate depression as endogenous anti-epileptic mechanism ENDOGENOUS AEDparticipant100.0002
2012-01-01Functional and Mecahnistic Roles of Large Intergenic Non-coding RNAs in Cancer CANCERLINCparticipant1.500.0001
2011-12-01Markers for Sub-Clinical Cardiovascular Risk Assessemnt EU-MASCARAparticipant5.990.88016
2011-11-01Evaluation of metastatic and angiogenic potential of cancer stem-like cells in distinct mouse models for lung and liver metastasis Metastasiscoordinator167.0661
2011-04-01NEW ADVANCED VACCINES IN CHRONIC HEPATITIS B NAVICHEBcoordinator100.0001
2011-01-01Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria AIPGENEcoordinator3.308.1547
2011-01-01The MEtabolic Road to DIAstolic Heart Failure MEDIAparticipant11.971.72121
2011-01-01Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis CURELUNGparticipant2.965.74911
2010-11-01Host and viral factors in acute hepatitis C HepaCuteparticipant2.999.50017

Alias institution names:

  • FUNDACION PARA LA INVESTIGACION MEDICA APLICADA